Search | Clinical Trials Finder

Conditions: Rett Syndrome
Interventions: Bionetide, Placebo; Drug
Lead sponsor: Biomed Industries, Inc.; Industry
Eligibility: 5 Years to 20 Years · Female only
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 14
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 11 more

Conditions: Vulvovaginal Candidiasis
Interventions: Ibrexafungerp; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 25
States / cities: Phoenix, Arizona • San Diego, California • Miami, Florida + 20 more

Conditions: Rheumatoid Arthritis
Interventions: prednisone; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Palm Harbor, Florida • Tampa, Florida

Conditions: Breast Cancer, Head and Neck Cancer, Lymphoma, Metastatic Cancer, Non-melanomatous Skin Cancer, Sarcoma
Interventions: silicon phthalocyanine 4; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Head and Neck Cancer
Interventions: computed tomography, cone-beam computed tomography, radiography, electronic portal imaging, image-guided adaptive radiation therapy; Procedure · Radiation
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 21 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer
Interventions: Infigratinib, Placebo; Drug
Lead sponsor: QED Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 47
States / cities: Tucson, Arizona • Duarte, California • Loma Linda, California + 39 more

Conditions: Healthy
Interventions: PF-04447943, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Glendale, California

Conditions: Bipolar 1 Disorder
Interventions: ELND005, Lamotrigine, Valproic acid, Placebo; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 41
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 36 more

Conditions: Oral Mucositis
Interventions: Gelclair, First® Mouthwash BLM; Device · Combination Product
Lead sponsor: Midatech Pharma US Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Duchenne Muscular Dystrophy
Interventions: PTC124; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 5 Years and older · Male only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 3
States / cities: Cincinnati, Ohio • Philadelphia, Pennsylvania • Salt Lake City, Utah

Conditions: Biological Availability, Healthy Participants
Interventions: Nirmatrelvir/ ritonavir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Meningitis, Cryptococcal, HIV Infections
Interventions: Fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: Oakland, California • New York, New York • Philadelphia, Pennsylvania

Conditions: Ankylosing Spondyloarthritis
Interventions: Apremilast tablet 20 mg, Apremilast tablet 30 mg BID, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 20
States / cities: Peoria, Arizona • La Jolla, California • Palm Desert, California + 17 more

Conditions: Neoplasm, Cancer, Tumors
Interventions: TKI258; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 4
States / cities: Scottsdale, Arizona • Durham, North Carolina • Nashville, Tennessee + 1 more

Conditions: Head and Neck Cancer
Interventions: cisplatin-e therapeutic implant; Drug
Lead sponsor: Matrix Pharmaceutical; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 26
States / cities: Tucson, Arizona • Los Angeles, California • Palo Alto, California + 21 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, PF-00734200 10 mg QD, PF-00734200 20 mg QD, PF-00734200 5 mg QD, PF-00734200 2 mg QD; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 64
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 49 more

Conditions: Meningitis, Cryptococcal, HIV Infections
Interventions: Fluconazole, Amphotericin B; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 28
States / cities: Los Angeles, California • Miami, Florida • Indianapolis, Indiana + 15 more

Conditions: Milk Allergy
Interventions: omalizumab; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 4 Years to 18 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 2
States / cities: Stanford, California • Boston, Massachusetts

Conditions: Healthy
Interventions: [¹⁴C]-LY3337641; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis
Interventions: CD101, Caspofungin, Fluconazole, intravenous placebo, oral placebo; Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 16
States / cities: Birmingham, Alabama • Davis, California • Miami, Florida + 12 more

Conditions: Pulmonary Hypertension Associated With Interstitial Lung Disease
Interventions: Placebo, Seralutinib, Generic Dry Powder Inhaler; Drug · Device
Lead sponsor: GB002, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Fresno, California • Albuquerque, New Mexico • Richmond, Virginia

Conditions: Type 2 Diabetes Mellitus
Interventions: Metformin immediate release (IR), Saxagliptin, Metformin IR, Saxagliptin/Metformin XR FDC, Metformin XR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Little Rock, Arkansas • Los Angeles, California • Louisville, Kentucky + 3 more

Conditions: Psoriasis
Interventions: LD-Aminopterin oral capsule, Placebo oral capsule; Drug
Lead sponsor: Syntrix Biosystems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Scottsdale, Arizona • Seattle, Washington • Spokane, Washington

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: doxorubicin hydrochloride, motexafin gadolinium; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Madison, Wisconsin

Search by objective public record fields.

To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome

Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis

A Safety Analysis of Oral Prednisone as a Pre-Treatment for Rituximab in Rheumatoid Arthritis.

Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin

Image-Guided Adaptive Radiotherapy for in Detecting Tumors During Treatment in Patients With Head and Neck Cancer

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

Study Of Single Ascending And Multiple Doses Of PF-04447943 In Japanese Subjects.

Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder

Gelclair at Conditioning or After Oral Mucositis Diagnosed vs. Magic Mouth Wash in Stem Cell Transplant Recipients

Safety and Efficacy Study of PTC124 in Duchenne Muscular Dystrophy

Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants

Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis

Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis

Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors

Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer

12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin

Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS

Xolair Treatment for Milk Allergic Children

A Study of LY3337641 in Healthy Male Participants

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM

Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer